VBL Therapeutics’ lead oncology product candidate, VB-111 (ofranergene obadenovec), is a targeted anti-cancer gene-based biologic agent that is positioned to potentially treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months.
The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor.
VB-111 has been observed to be well-tolerated in >300 cancer patients and we have observed its preliminary activity in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies, for recurrent Gliblastoma (rGBM), Ovarian cancer and Thyroid cancer. VB-111 is currently being studied in a Phase 3 pivotal trial for rGBM, conducted under an FDA Special Protocol Assessment (SPA) and in a Phase 3 pivotal trial for Platinum Resistant Ovarian Cancer.
Glioblastoma is a brain cancer that affects approximately 10,000-12,000 newly diagnosed people each year in the United States. It is a devastating, rapidly progressing tumor, with a median time from diagnosis to the patient’s death of 12 to 15 months. In rGBM, treatment consists of both symptomatic and palliative therapies. However, with currently available therapies, glioblastoma typically remains fatal.
According to the National Cancer Institute, in 2017, it is estimated that there will be 56,870 new cases of Thyroid cancer and an estimated 2,010 people will die of this disease. The American Cancer Society estimates that in 2017, about 22,440 women will be diagnosed with Ovarian cancer in the United States and about 14,080 women will die from ovarian cancer.